ROQUEFORT THERAPEUTICS PLC

Share Issue/Capital Change • Sep 15, 2022

National Storage Mechanism | Additional information

RNS Number : 6340Z

Roquefort Therapeutics PLC

15 September 2022

15 September 2022

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Notice of Admission

Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, confirms that application has been made to the Financial Conduct Authority and the London Stock Exchange for a total of 57,249,998 new Ordinary Shares, comprising 50,000,000 Consideration Shares and 7,249,998 Placing Shares of £0.01 each, to the Official List of the UKLA by way of a standard listing under Chapter 14 of the UKLA's Listing Rules and to trading on the London Stock Exchange's main market for listed securities ("Admission"). Admission will take place at 8:00a.m. tomorrow.

Completion of the Acquisition and the Placing will become effective on Admission.

Capitalised terms used in this announcement (unless otherwise defined) carry the same meanings as those ascribed to them in the Company's Prospectus dated 13 September 2022, unless the context requires otherwise.

The Prospectus and further information on the Company can be found on Roquefort Therapeutic's website at: https://www.roquefortplc.com

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

-Ends-

Enquiries:

Roquefort Therapeutics plc
Stephen West (Chairman)	+44 (0)20 3290 9339
Hybridan LLP (Joint Broker) Claire Louise Noyce Optiva Securities Limited (Joint Broker)	+44 (0)203 764 2341
Christian Dennis Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale	+44 (0)20 3411 1881 +44 (0)20 7466 5000

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines.  The highly complementary profile of four best-in-class medicines consists of:

·    Midkine antibodies with significant in vivo efficacy and toxicology studies;

·    Midkine RNA therapeutics with novel anti-cancer gene editing action;

·    MK cell therapy with direct and NK-mediated anti-cancer action; and

·    siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSEAFNSFALAEFA